395 results on '"Lindhoff-Last, E."'
Search Results
2. LB 02.4 Anti-Platelet Factor 4 Induced Immunothrombosis Independent of Heparin or Vaccination
3. Moderne Therapie tiefer Venenthrombosen und der Lungenarterienembolie
4. Blutungs- und Gerinnungsstörungen
5. Hämorrhagische Diathesen
6. Vaskulitis, Thrombophlebitits
7. Various Missense Mutations in the Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Cause Hereditary Coumarin Resistance
8. Blutungs- und Gerinnungsstörungen
9. Hereditäre Thrombophilie
10. Virchow-Trias
11. Thrombogenität verschiedener Krankheitsbilder
12. Gerinnungskaskade
13. Molecular Genetic Analysis in Patients with Inherited Thrombophilia and Antithrombin, Protein C or Protein S Deficiency
14. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
15. A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system
16. Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene
17. pAVK konservativ
18. Zufallsbefund pathologischer Gerinnungsparameter
19. Massive Beinschwellung und prätibiale Ulzerationen nach Hüftgelenksoperation
20. Hämostase
21. Screening for lupus anticoagulants in patients treated with vitamin K antagonists
22. Heparin‐induced non‐necrotizing skin lesions: rarely associated with heparin‐induced thrombocytopenia
23. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia
24. Reduzieren Statine das Rezidivrisiko für arterielle Lungenembolien oder tiefe Beinvenenthrombosen?: Ist der Einsatz zur Sekundärprävention sinnvoll?
25. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti–beta2 glycoprotein-1 antibodies
26. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary
27. Stellenwert der Thrombozytenfunktionsdiagnostik
28. Therapie der venösen Thromboembolie
29. Medikamentöse Therapie bei interventionellen Eingriffen am peripheren Gefäßsystem
30. Unterschiede in der Thrombogenese in Chirurgie und Innerer Medizin
31. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements
32. Are point-of-care devices useful for monitoring bleeding risk under rivaroxaban treatment?: PO 265
33. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) - final results from the GerHIT multi-centre registry study: PB 4.40–1
34. Incidence of heparin-induced skin lesions in postmenopause: PB 3.39–6
35. High risk of nadroparin to induce cutaneous delayedtype IV hypersensitivity reactions (DTH): PB 3.39–4
36. Low incidence of heparin-induced skin lesions in orthopedic surgery patients: PB 3.39–5
37. Off-label use of fondaparinux in suspected acute heparin-induced thrombocytopenia (HIT) - final results from the GerHIT multicentre, retrospective registry study: PA 3.08–1
38. Danaparoid (Orgaran) zur Antikoagulation bei der maschinellen Autotransfusion mit Cell Saver 5 (Haemonetics)
39. High incidence of heparin-induced allergic skin reactions in pregnancy: FV02/05
40. Real world experience from 1000 patients. Preprocedural DOAC interruption impacts detectable DOAC serum levels but not adverse events after catheter ablation of atrial fibrillation
41. Hereditary warfarin resistance in 16 patients due to nine novel and three known VKORC1 mutations: OC-WE-077
42. The influence of heparinʼs molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157: 514–17
43. Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin
44. Management of Cutaneous Heparin Hypersensitivity Reactions
45. β2-Glycoprotein I IgA antibodies and ischaemic stroke: reply
46. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke
47. Anticoagulation of Pregnant Women With Mechanical Heart Valves Using Low-Molecular-Weight Heparin
48. Determination of heparin–platelet factor 4–IgG antibodies improves diagnosis of heparin-induced thrombocytopenia
49. Therapie des Antiphospholipid-Syndroms (APS) mit DOAKs
50. Therapie des Antiphosphoplidsyndrom (APS) mit DOAK
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.